title: Temozolomide and other potential agents for the treatment of glioblastoma multiforme.
abstract: This article provides historical and recent perspectives related to the use of temozolomide for the treatment of glioblastoma multiforme. Temozolomide has quickly become part of the standard of care for the modern treatment of stage IV glioblastoma multiforme since its approval in 2005. Yet despite its improvements from previous therapies, median survival remains approximately 15 months, with a 2-year survival rate of 8% to 26%. The mechanism of action of this chemotherapeutic agent, conferred advantages and limitations, treatment resistance and rescue, and potential targets of future research are discussed.
authors.affiliation: UCLA Department of Neurosurgery, University of California Los Angeles, David Geffen School of Medicine at UCLA, 695 Charles East Young Drive South, UCLA Gonda 3357, Los Angeles, CA 90095-1761, USA.
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Nagasawa
authors.forename: Frances
authors.initials: F
authors.lastname: Chow
authors.forename: Andrew
authors.initials: A
authors.lastname: Yew
authors.forename: Won
authors.initials: W
authors.lastname: Kim
authors.forename: Nicole
authors.initials: N
authors.lastname: Cremer
authors.forename: Isaac
authors.initials: I
authors.lastname: Yang
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy*; D006801:Humans; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide